BRPI0915105A2 - composto de 2,4'-biripidinila como inibidores da proteína cinase d úteis para o tratamento de ia insuficiência cardíaca e cancer - Google Patents

composto de 2,4'-biripidinila como inibidores da proteína cinase d úteis para o tratamento de ia insuficiência cardíaca e cancer

Info

Publication number
BRPI0915105A2
BRPI0915105A2 BRPI0915105A BRPI0915105A BRPI0915105A2 BR PI0915105 A2 BRPI0915105 A2 BR PI0915105A2 BR PI0915105 A BRPI0915105 A BR PI0915105A BR PI0915105 A BRPI0915105 A BR PI0915105A BR PI0915105 A2 BRPI0915105 A2 BR PI0915105A2
Authority
BR
Brazil
Prior art keywords
biripidinyl
cancer
compound
treatment
heart failure
Prior art date
Application number
BRPI0915105A
Other languages
English (en)
Inventor
Rao Chang
Francis Jewell Charles Jr
Meredith Erik
G Gamber Gabriel
Miranda Karl
G Monovich Leuran
Dpietro Lucian
Paul Capparelli Michael
Soldermann Nicolas
Zhu Qingming
Burgis Robin
Yoon Taeyoung
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0915105A2 publication Critical patent/BRPI0915105A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
BRPI0915105A 2008-06-13 2009-06-12 composto de 2,4'-biripidinila como inibidores da proteína cinase d úteis para o tratamento de ia insuficiência cardíaca e cancer BRPI0915105A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6138408P 2008-06-13 2008-06-13
PCT/EP2009/057298 WO2009150230A1 (en) 2008-06-13 2009-06-12 2,4'-bipyridinyl compounds as protein kinase d inhibitors useful for the treatment of ia heart failure and cancer

Publications (1)

Publication Number Publication Date
BRPI0915105A2 true BRPI0915105A2 (pt) 2019-09-24

Family

ID=40941599

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0915105A BRPI0915105A2 (pt) 2008-06-13 2009-06-12 composto de 2,4'-biripidinila como inibidores da proteína cinase d úteis para o tratamento de ia insuficiência cardíaca e cancer

Country Status (11)

Country Link
US (1) US20110092505A1 (pt)
EP (1) EP2310381A1 (pt)
JP (1) JP2011522865A (pt)
KR (1) KR20110031318A (pt)
CN (1) CN102137856A (pt)
AU (1) AU2009256574A1 (pt)
BR (1) BRPI0915105A2 (pt)
CA (1) CA2727680A1 (pt)
EA (1) EA201100136A1 (pt)
MX (1) MX2010013773A (pt)
WO (1) WO2009150230A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102171189B (zh) * 2008-07-31 2013-11-20 詹森药业有限公司 作为快速解离多巴胺2受体拮抗剂的哌嗪-1-基-三氟甲基取代的吡啶
US8415381B2 (en) * 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
AU2010333804B2 (en) 2009-12-23 2015-07-16 Takeda Pharmaceutical Company Limited Fused heteroaromatic pyrrolidinones as syk inhibitors
WO2011130515A1 (en) * 2010-04-14 2011-10-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Arylthiazolyl piperidines and related compounds as modulators of survival motor neuron (smn) protein production
US8273142B2 (en) * 2010-09-02 2012-09-25 Cabot Microelectronics Corporation Silicon polishing compositions with high rate and low defectivity
WO2012177714A1 (en) 2011-06-22 2012-12-27 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
CN103923085B (zh) * 2013-02-25 2016-08-24 苏州云轩医药科技有限公司 具有刺猬通路拮抗剂活性的吡啶杂环化合物及其用途
EP3030902B1 (en) 2013-08-07 2019-09-25 Friedrich Miescher Institute for Biomedical Research New screening method for the treatment friedreich's ataxia
ES2699354T3 (es) 2014-01-17 2019-02-08 Novartis Ag Derivados de 1-(triazin-3-il/piridazin-3-il)-piper(-azin)idina y composiciones de las mismas para inhibir la actividad de SHP2
US10093646B2 (en) 2014-01-17 2018-10-09 Novartis Ag 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
MA39823A (fr) 2014-04-03 2018-01-09 Janssen Pharmaceutica Nv Dérivés de pyridine macrocyclique
MA39822A (fr) 2014-04-03 2018-02-06 Janssen Pharmaceutica Nv Dérivés de pyrimidine bicycle
AU2016211630B2 (en) 2015-01-26 2021-03-25 University Of Washington Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases
ES2805232T3 (es) 2015-06-19 2021-02-11 Novartis Ag Compuestos y composiciones para inhibir la actividad de SHP2
ES2824576T3 (es) 2015-06-19 2021-05-12 Novartis Ag Compuestos y composiciones para inhibir la actividad de SHP2
EP3310779B1 (en) 2015-06-19 2019-05-08 Novartis AG Compounds and compositions for inhibiting the activity of shp2
US11925628B2 (en) * 2015-06-30 2024-03-12 Shanghai Jiao Tong University Applications for nicardipine in preparing anti-lung cancer products
CN109415360B (zh) 2016-06-14 2021-11-02 诺华股份有限公司 用于抑制shp2活性的化合物和组合物
WO2018078083A1 (en) * 2016-10-28 2018-05-03 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for treating multiple myeloma
US20190343836A1 (en) 2017-01-10 2019-11-14 Novartis Ag Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor
ES3032793T3 (en) * 2018-04-10 2025-07-24 Neuropore Therapies Inc Tri-substituted aryl and heteroaryl derivatives as modulators of pi3-kinase and autophagy pathways
CN112334457A (zh) 2018-06-22 2021-02-05 拜耳公司 制备三环化合物的方法
CN111662283B (zh) * 2019-03-07 2021-11-16 湖南化工研究院有限公司 咪唑并吡啶类化合物及其中间体、制备方法与应用
US12522606B2 (en) 2020-01-09 2026-01-13 University Of Washington Modified pyrrolo- and pyrazolo-pyrimidines for prostate cancer therapy
CN112451529A (zh) * 2020-12-18 2021-03-09 忻佑康医药科技(南京)有限公司 Kb-NB 142-70的药物新用途
CA3240263A1 (en) 2021-12-09 2023-06-15 Daniel L. Flynn Raf kinase inhibitors and methods of use thereof
CN115449434B (zh) * 2022-10-13 2023-11-17 江西安邦药业有限公司 一种桉油连续分级精馏的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2230392A1 (de) * 1972-06-22 1974-01-31 Cassella Farbwerke Mainkur Ag Substituierte pyridinverbindungen und verfahren zu ihrer herstellung
WO2007125331A2 (en) * 2006-04-26 2007-11-08 Cancer Research Technology Limited Amino-ethyl-amino-aryl (aeaa) compounds and their use
PT2144909E (pt) * 2007-04-06 2011-06-29 Novartis Ag [2,6]naftiridinas úteis como inibidores de proteínas quinases

Also Published As

Publication number Publication date
AU2009256574A1 (en) 2009-12-17
JP2011522865A (ja) 2011-08-04
EA201100136A1 (ru) 2011-08-30
CA2727680A1 (en) 2009-12-17
WO2009150230A1 (en) 2009-12-17
MX2010013773A (es) 2011-01-21
EP2310381A1 (en) 2011-04-20
US20110092505A1 (en) 2011-04-21
KR20110031318A (ko) 2011-03-25
CN102137856A (zh) 2011-07-27

Similar Documents

Publication Publication Date Title
BRPI0915105A2 (pt) composto de 2,4'-biripidinila como inibidores da proteína cinase d úteis para o tratamento de ia insuficiência cardíaca e cancer
LTC2137143I2 (lt) Pleuromutilino dariniai, skirti mikrobų sukeltų ligų gydymui
BRPI0812293A2 (pt) Derivados de 2-oxo-3-benzilbenzoxazol-2 -ona e compostos relacionados como inibidores de met quinase para o tratamento de tumores
BRPI1012116A2 (pt) composição farmacêutica para o tratamento de doenças cardíacas
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
HUE054495T2 (hu) Rák kezelésére szolgáló készítmény
BRPI0813311A2 (pt) Composto, métodos para modulara a atividade de uma proteína quinase e para tratar câncer em um indivíduo, e, composição farmacêutica.
BRPI0915112A2 (pt) cateter de entalhe para tratar válvulas cardíacas doentes
BRPI0816784A2 (pt) Fatores neuro-endócrinos para o tratamento de doenças degenerativas
BRPI0716844A2 (pt) Inidores de quinase úteis para o tratamento de doenças proliferativas
BRPI0807717A2 (pt) Inibidores de quinase úteis para o tratamento de doenças mieloproliferativas e outras doenças proliferativas.
SMP200900085B (it) 3-imidazolil-indoli per il trattamento di malattieproliferative.
BRPI0807987A2 (pt) Terapia de combinação para tratamento de distúrbios imunes.
BRPI0911577A8 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
EP2327448A4 (en) defibrillation catheter
BRPI0821660A2 (pt) Combinações de agentes terapêuticos para tratamento de câncer
PT2367561E (pt) Composições e métodos para o tratamento da doença celíaca
IT1391555B1 (it) Apparato trattamento extracorporeo sangue
HRP20181727T1 (hr) Upotreba protutijela protiv čimbenika xi, namijenjena sprečavanju ili liječenju stvaranja krvnog ugruška
PT2056814E (pt) Compostos de 2,5-di-hidroxibenzeno para o tratamento da psoríase
BRPI0914555A2 (pt) derivados de triazol bicíclicos para o tratamento de tumores
BRPI0908635A2 (pt) composto, composição farmacêutica e método de tratamento de câncer
BRPI0816712A2 (pt) terapia de intervalo para o tratamento de tinnitus
BR112012003372A2 (pt) vitamina d3 e análogos da mesma para o tratamento de alopecia.
BRPI0908181A2 (pt) Solução de cardioplegia para cirurgia cardíaca

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.